PT-141
Also known as: Bremelanotide
Molecular Identifiers
Overview
Melanocortin MC4R receptor agonist. Research in sexual function. Effects last 6-12 hours. On-demand use.
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH Cyclic peptide with non-natural amino acids
Half-life
~2-3 hours
Administration Route
Subcutaneous
Category
Cosmetic & Skin
Mechanism of Action
- Selective MC4R receptor agonism in the CNS
- Activation of central dopaminergic pathways
- Vascular system-independent effect (unlike PDE5 inhibitors)
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 500-2000 mcg per injection |
| Frequency | As needed, maximum 2-3x/week |
| Timing | 1-2 hours before desired effect |
| Duration | On-demand use |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Nausea
- Facial flushing
- Headache
- Transient blood pressure increase
Presentations & Preparation
Vials of PT-141 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on PT-141.
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH
Related Peptides
Acetyl Octapeptide-1
Topical 3-5% · Twice daily
AHK-Cu
Topical or 200-500 mcg subcutaneous · 1-2 times daily (topical), every other day (subcutaneous)
Argireline
Topical 5-10% or 100-250 mcg subcutaneous · Topical twice daily, subcutaneous 2-3x per week
Decapeptide-12
Topical application · 1-2 times daily
GHK Basic
Topical or 200-600 mcg subcutaneous · 1-2 times daily (topical), every other day (subcutaneous)
Matrixyl
Topical application · 1-2 times daily